Skip to content Go to the main menu Go to the search form Go to the footer menu

DEVELOPMENT pipeline

Oncology

solid tumors

CompoundDarovasertib
TargetPKC
Therapeutic areas

Uveal melanoma

Phase
PCD
1/2
2
3
CompoundIvosidenib
TargetIDH1
Therapeutic areas

Chondrosarcoma

Phase
PCD
1/2
2
3
CompoundIvosidenib/
+ durvalumab + gemcitabine/cisplatine
TargetIDH1
Therapeutic areas

Cholangiocarcinoma

Phase
PCD
1/2
2
3
CompoundVorasidenib/
+ temozolomide
TargetIDH1/2
Therapeutic areas

Glioma

Phase
PCD
1/2
2
3
CompoundVorasidenib/
+ pembrolizumab
TargetIDH1/2
Therapeutic areas

Glioma

Phase
PCD
1/2
2
3
CompoundS095018
(in association)
TargetTIM3
Therapeutic areas

Non-small Cell Lung Cancer

Phase
PCD
1/2
2
3
CompoundS095024
(in association)
TargetCD73
Therapeutic areas

Non-small Cell Lung Cancer

Phase
PCD
1/2
2
3
CompoundS095029
(in association)
TargetNKG2A
Therapeutic areas

Non-small Cell Lung Cancer

Phase
PCD
1/2
2
3
CompoundS095029
(in association)
TargetNKG2A
Therapeutic areas

Gastric cancer

Phase
PCD
1/2
2
3
CompoundS095035
TargetMAT2A
Therapeutic areas

Solid tumors

Phase
PCD
1/2
2
3
CompoundS241656
TargetRAS, RAF
Therapeutic areas

Solid tumors

Phase
PCD
1/2
2
3

hematological malignancies

CompoundIvosidenib/
+ 7+3 (chemotherapy)
TargetIDH1
Therapeutic areas

Acute Myeloid Leukemia

Phase
PCD
1/2
2
3
CompoundIvosidenib /
azacitidine / venetoclax
TargetIDH1
Therapeutic areas

Acute Myeloid Leukemia

Phase
PCD
1/2
2
3
CompoundIvosidenib
TargetIDH1
Therapeutic areas

Acute Myeloid Leukemia

Phase
PCD
1/2
2
3
CompoundCemacastagene / Ansegedleucel
(Cema-Cel)*
TargetCD19
Therapeutic areas

Diffuse Large B-Cell Lymphoma

Phase
PCD
1/2
2
3
CompoundS243249
TargetMENIN
Therapeutic areas

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia

Phase
PCD
1/2
2
3
CompoundS236220
TargetND**
Therapeutic areas

Hematological malignancies

Phase
PCD
1/2
2
3
CompoundS247567
TargetND**
Therapeutic areas

Hematological malignancies

Phase
PCD
1/2
2
3

• Neurology

CompoundS247240
Chemical entity
TargetBK channel
Therapeutic areas

Fragile X syndrome is a genetic disorder caused by a mutation in the FMR1 gene, leading to a deficiency of the fragile X mental retardation protein (FMRP). This protein is crucial for normal brain development and function. The absence of FMRP disrupts synaptic plasticity, which is essential for learning and memory, resulting in cognitive impairments and behavioral challenges.​

Patients with Fragile X syndrome often exhibit a range of symptoms, including intellectual disability, anxiety, and social difficulties. The condition can also manifest itself through physical features such as an elongated face and enlarged ears.

Phase
PCD
1/2
2
3
CompoundS230815
AntiSense Oligonucleotide
TargetKCNT1
Therapeutic areas

KCNT1-related Developmental and Epileptic Encephalopathy (DEE) are a group of severe neurological disorders characterized by very early-onset seizures and significant developmental delays. KCNT1-DEE is caused by genetic mutations in the KCNT1 gene that disrupt normal brain development and function. The seizures are most often refractory to standard anti-epileptic medication, complicating treatment.

Patients with KCNT1-DEE experience a range of symptoms, including severe cognitive impairments, motor deficits, and behavioral issues. The impact on family dynamics and overall quality of life is profound.

More details about ASO technology

Phase
PCD
1/2
2
3
CompoundS233107
TargetND**
Therapeutic areas

Movement disorders are a diverse group of neurological conditions characterized by abnormal movements that significantly impact daily functioning. These disorders are often due to genetic mutations, neurodegenerative processes, or environmental factors affecting the brain’s motor control pathways. Common examples include sustained muscle contractions and abnormal postures, as  irregular, rapid movements difficult to control.

Patients with rare movement disorders often face challenges in mobility, communication, and social interactions. The unpredictability of symptoms is often associated with emotional distress and a reduced quality of life.

Phase
PCD
1/2
2
3

Cardiometabolism & Venous diseases

CompoundIvabradine
(new formulation)
Target
Therapeutic areas

Heart Failure

Phase
PCD
1/2
2
3
RA
CompoundDapagliflozin / Bisoprolol
Target
Therapeutic areas

Heart Failure

Phase
PCD
1/2
2
3
RA
CompoundBisoprolol / Perindopril / Indapamide / Amlodipine
Target
Therapeutic areas

Hypertension

Phase
PCD
1/2
2
3
RA
CompoundPerindopril / Indapamide SR / Amlodipine
Target
Therapeutic areas

Hypertension

Phase
PCD
1/2
2
3
RA
CompoundGliclazide / Metformin
Target
Therapeutic areas

T2 diabetes

Phase
PCD
1/2
2
3
RA
CompoundBisoprolol / Perindopril / Amlodipine
Target
Therapeutic areas

Hypertension

Phase
PCD
1/2
2
3
RA
CompoundDapagliflozin / Gliclazide
(2 formulations)
Target
Therapeutic areas

T2 diabetes

Phase
PCD
1/2
2
3
RA

PCD = Preclinical development phase, 1/2 = Phase 1/2, 2 = Phase 2, 3 = Phase 3, RA = Under regulatory authorities evaluation
* Cema-Cel (ALLO501.A /S 95023) utilize TALEN® gene-editing technology owned by Cellectis. Servier, which has an exclusive license to the anti-CD19 investigational products from Cellectis, has granted Allogene exclusive rights to develop and commercialize Cema-Cel in the U.S., all EU Member States and the United Kingdom. For other candidate products (UCART19v1 and ALLO 501) sub-licensed to Allogene,  the ongoing activities are limited to follow up of patients from discontinued trials as per regulatory obligations.
** Not Disclose